Dyne Therapeutics 株価情報 (NASDAQ: DYN)

最新ニュース Dyne Therapeutics (NASDAQ:DYN) 株価情報

Dyne Therapeutics

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Dyne Therapeutics Inc

DYNASTAR HOLDINGS INC by Dynastar Holdings, Inc.

Dynastar Holdings Inc

Dye & Durham Ltd

DynTek, Inc. Com

iShares U.S. Equity Factor Rotation Active ETF

IDX Dynamic Innovation ETF

DynaResource Inc

Dynatronics Corp

Dynamix Corp

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $50 price target.

News

Price Target

Analyst Ratings

Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $50 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $55 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $55 Price Target

WIIM

Dyne Therapeutics shares are trading higher. The company reported Q3 financial results and provided updates on its balance sheet.

Biotech

Earnings

Guidance

Health Care

General

Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.78) by 23.08 percent. This is a 3.03 percent increase over losses of $(0.99) per share from the same period last year.

Dyne Therapeutics Q3 2024 GAAP EPS $(0.96) Misses $(0.78) Estimate

Dyne Therapeutics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $43 to $35.

JP Morgan analyst Tessa Romero downgrades Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) from Overweight to Neutral and lowers the price target from $43 to $35.

Downgrades

JP Morgan Downgrades Dyne Therapeutics to Neutral, Lowers Price Target to $35

Dyne Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NYSE">DYN</a>) short percent of float has risen 15.97% since its last report. The company recently reported that it has 8.88 million shares sold short, which is 10.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dyne Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729627225_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dyne Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dyne Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dyne Therapeutics's peer group average for short interest as a percentage of float is 15.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Dyne Therapeutics's Recent Short Interest

Dyne Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NYSE">DYN</a>) short percent of float has risen 11.55% since its last report. The company recently reported that it has 7.66 million shares sold short, which is 9.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dyne Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727716523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dyne Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dyne Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dyne Therapeutics's peer group average for short interest as a percentage of float is 15.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Dyne Therapeutics's Recent Short Interest

Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Overweight and maintains $53 price target.

Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $53 Price Target

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 2% on Tuesday.
The Dow traded down 1.49% to 40,944.47 while the NASDAQ fell 3.07% to 17,169.68. The S&amp;P 500 also fell, dropping, 2% to 5,535.29.
Check This Out:<a href="https://www.benzinga.com/news/earnings/24/09/40679816/dow-hits-record-high-s-p-500-gains-for-4th-consecutive-month-fear-index-in-greed-zone"> Dow Hits Record High, S&amp;P 500 Gains For 4th Consecutive Month: Fear Index In &#8216;Greed&#8217; Zone</a>
Leading and Lagging Sectors Consumer staples shares climbed by 1% on Tuesday.
In trading on Tuesday, information technology shares fell by 3.7%.
Top Headline
U.S. construction spending declined by 0.3% month-over-month to an annual rate of $2,162 billion in July.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares shot up 112% to $0.7017. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>Shares of SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) got a boost, surging 65% to $2.3950 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares were also up, gaining 83% to $1.2089 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
</ul>
Equities Trading DOWN
<ul>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares dropped 31% to $1.0299 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Shares of Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) were down 35% to $30.17. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) was down, falling 16% to $6.11. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).</li>
</ul>
Commodities In commodity news, oil traded down 4.5% to $70.21 while gold traded down 0.3% at $2,521.10.
Silver traded down 2.7% to $28.345 on Tuesday, while copper fell 2.9% to $4.0910.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.97%, Germany's DAX fell 0.97% and France's CAC 40 fell 0.93%. Spain's IBEX 35 Index fell 1.02%, while London's FTSE 100 fell 0.78%.
French government budget deficit shrank to EUR 156.91 billion in January to July compared to EUR 168.99 billion in the year-ago period last year. The number of people registering as jobless in Spain increased by 0.9% month-over-month to 2.6 million in August. UK's retail sales increased 0.8% year-over-year in August.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.04%, Hong Kong's Hang Seng Index falling 0.23%, China's Shanghai Composite Index declining 0.29% and India's BSE Sensex falling 0.005%.
Singapore's manufacturing PMI rose to 50.9 in August from 50.7 in the prior month.
Economics
<ul>
<li>The Logistics Manager's Index fell to 56.4 in August compared to 56.5 in July.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to 47.9 in August versus a preliminary reading of 48.</li>
<li>The ISM manufacturing PMI rose to 47.2 in August from 46.8 in the prior month, missing market estimates of 47.5.</li>
<li>U.S. construction spending declined by 0.3% month-over-month to an annual rate of $2,162 billion in July.</li>
<li>The RealClearMarkets/TIPP Economic Optimism Index rose by 1.6 points to a reading of 46.1 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

CNFR

IOBT

RXRX

SGRP

SIFY

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Outperform and maintains $55 price target.

Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $55 Price Target

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).
Nikola shares dipped 10.4% to $7.28 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares jumped 103% to $0.6719. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 85% to $3.70.</li>
<li>SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) surged 65% to $2.3950 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) rose 62.7% to $2.31.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares jumped 56% to $1.0250 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) gained 44.6% to $1.25 after the company announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application.</li>
<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) surged 43.5% to $115.92 after the company announced it selected VAX-31 to advance to an adult Phase 3 program following topline results from its Phase 1/2 study.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) jumped 17.5% to $6.55 after the company announced it dosed 5 new patients in its ACHIEVE Phase 2b trial.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 16.5% to $1.27.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) surged 15.8% to $2.34.</li>
<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) gained 15.3% to $1.73. MediciNova recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 for post-COVID conditions.</li>
<li>GD Culture Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) rose 12.8% to $6.86.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) jumped 12.6% to $5.99.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) gained 11.4% to $8.29.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) rose 11.3% to $1.3250.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) climbed 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) gained 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares dipped 42.2% to $4.68.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) fell 31.7% to $31.47. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 31.3% to $1.75 after jumping 60% on Friday.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) dipped 29.3% to $1.06 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) fell 25.8% to $1.1499. Brenmiller recently reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) dipped 22.8% to $1.13.</li>
<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEDU#NYSE">FEDU</a>) fell 21.8% to $13.30.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) declined 21.6% to $3.55.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 18.8% to $1.5506.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) dipped 18.6% to $3.99.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 16.1% to $8.49.</li>
<li>LightInTheBox Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NASDAQ">LITB</a>) declined 14.3% to $0.4455.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) fell 12.7% to $16.97 as the company announced planned CEO transition.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) fell 10.8% to $4.2350.</li>
<li>Nova Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) declined 9.6% to $202.16.</li>
<li>Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) fell 8.5% to $81.15.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) fell 8.5% to $109.35.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 8.3% to $159.27 ahead of the September 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) dipped 8% to $75.43.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 7.2% to $70.73.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) declined 7% to $20.52.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.2% to $185.01.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Movers

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

FEDU

GERN

INTC

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

SHLS

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

On Tuesday, Dyne Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40682278/dyne-therapeutics-announces-new-clinical-data-from-phase-12-deliver-trial-of-dyne-251-in-duchenne-" rel="noreferrer noopener">amenable to exon 51 skipping</a>.
This assessment of the DELIVER trial evaluating DYNE-251 includes 6-month biomarker and functional data from 8 male patients enrolled in the 20 mg/kg (approximate PMO dose) cohort who were randomized to receive DYNE-251 or placebo once every four weeks and 12-month functional data from 6 participants in the 10 mg/kg cohort.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38925997/why-is-dyne-therapeutics-stock-soaring-on-monday" rel="noreferrer noopener">Why Is Dyne Therapeutics Stock Soaring On Monday?</a>
At a 20-mg/kg dose level, given every four weeks, DYNE-251 resulted in a mean absolute dystrophin expression of 3.71% of normal, without adjusting for muscle content.
The company noted that the expression level is more than ten times higher than in a reference clinical trial assessing the weekly standard of care treatment Sarepta Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) EXONDYS 51 (eteplirsen), where dystrophin expression was at 0.3% normal.
After controlling for patients&#8217; muscle content, the company said that the mean absolute dystrophin expression jumped to 8.72%, which exceeds levels typically recorded in studies evaluating other investigational oligomers for DMD.
These results are in line with&nbsp;six-month data&nbsp;Dyne released in May for patients treated with the 10-mg/kg <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38925997/why-is-dyne-therapeutics-stock-soaring-on-monday" rel="noreferrer noopener">dose of DYNE-251</a>.
Patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change (unadjusted for muscle content) from baseline at&nbsp;six&nbsp;months.&nbsp;
When adjusting for muscle content, the&nbsp;DYNE-251 treated&nbsp;group reached 7.64% mean absolute dystrophin.
Dyne Therapeutics says&nbsp;meaningful improvements in multiple functional endpoints were observed in the 20 mg/kg and 10 mg/kg DYNE-251 Q4W groups. The 10 mg/kg cohort showed continued improvement in all reported measures from 6 to 12 months.
DYNE-251 demonstrated a favorable safety profile, and most treatment-emergent adverse events were mild or moderate.
Dyne says it is initiating registrational cohorts in the DELIVER trial and plans to provide an update on the path to registration by the end of 2024.
Price Action: DYN stock is down 31.90% at $31.39 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40688264/bacterial-infections-vaccine-developer-vaxcytes-pneumococcal-shot-shows-promise-in-mid-stage-tria" target="_blank" rel="noreferrer noopener">Bacterial Infections Vaccine Developer Vaxcyte&#8217;s Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher</a>.</li>
</ul>

SRPT

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 1% on Tuesday.
The Dow traded down 0.94% to 41,173.76 while the NASDAQ fell 2.22% to 17,320.89. The S&amp;P 500 also fell, dropping, 1.28% to 5,575.91.
Check This Out:<a href="https://www.benzinga.com/news/earnings/24/09/40679816/dow-hits-record-high-s-p-500-gains-for-4th-consecutive-month-fear-index-in-greed-zone"> Dow Hits Record High, S&amp;P 500 Gains For 4th Consecutive Month: Fear Index In &#8216;Greed&#8217; Zone</a>
Leading and Lagging Sectors Consumer staples shares climbed by 0.9% on Tuesday.
In trading on Tuesday, information technology shares fell by 3%.
Top Headline
The ISM manufacturing PMI rose to 47.2 in August from 46.8 in the prior month, missing market estimates of 47.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares shot up 105% to $0.68. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>Shares of SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) got a boost, surging 65% to $2.39 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares were also up, gaining 46% to $0.9604 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
</ul>
Equities Trading DOWN
<ul>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares dropped 28% to $1.08 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Shares of Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) were down 33% to $30.88. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) was down, falling 12% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).</li>
</ul>
Commodities In commodity news, oil traded down 4.2% to $70.45 while gold traded down 0.7% at $2,510.00.
Silver traded down 3.3% to $28.19 on Tuesday, while copper fell 3.5% to $4.0660.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.07%, Germany's DAX fell 1.04% and France's CAC 40 fell 1.06%. Spain's IBEX 35 Index fell 1.18%, while London's FTSE 100 fell 0.86%.
French government budget deficit shrank to EUR 156.91 billion in January to July compared to EUR 168.99 billion in the year-ago period last year. The number of people registering as jobless in Spain increased by 0.9% month-over-month to 2.6 million in August. UK's retail sales increased 0.8% year-over-year in August.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.04%, Hong Kong's Hang Seng Index falling 0.23%, China's Shanghai Composite Index declining 0.29% and India's BSE Sensex falling 0.005%.
Singapore's manufacturing PMI rose to 50.9 in August from 50.7 in the prior month.
Economics
<ul>
<li>The Logistics Manager's Index fell to 56.4 in August compared to 56.5 in July.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to 47.9 in August versus a preliminary reading of 48.</li>
<li>The ISM manufacturing PMI rose to 47.2 in August from 46.8 in the prior month, missing market estimates of 47.5.</li>
<li>U.S. construction spending declined by 0.3% month-over-month to an annual rate of $2,162 billion in July.</li>
<li>The RealClearMarkets/TIPP Economic Optimism Index rose by 1.6 points to a reading of 46.1 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Nasdaq Dips Over 2%; US Construction Spending Falls In July

U.S. stocks traded lower this morning, with the Dow Jones index falling over 1% on Tuesday.
Following the market opening Tuesday, the Dow traded down 1.09% to 41,109.54 while the NASDAQ fell 1.59% to 17,432.51. The S&amp;P 500 also fell, dropping, 1.22% to 5,579.37.
Check This Out:<a href="https://www.benzinga.com/news/earnings/24/09/40679816/dow-hits-record-high-s-p-500-gains-for-4th-consecutive-month-fear-index-in-greed-zone"> Dow Hits Record High, S&amp;P 500 Gains For 4th Consecutive Month: Fear Index In &#8216;Greed&#8217; Zone</a>
Leading and Lagging Sectors Consumer staples shares climbed by 0.4% on Tuesday.
In trading on Tuesday, energy shares fell by 3%.
Top Headline
The ISM manufacturing PMI rose to 47.2 in August from 46.8 in the prior month, missing market estimates of 47.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares shot up 110% to $0.6967. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>Shares of BranchOut Food Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) got a boost, surging 90% to $3.7990.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares were also up, gaining 73% to $1.14 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares dropped 33% to $1.71 after jumping 60% on Friday.</li>
<li>Shares of Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) were down 34% to $30.43. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) was down, falling 30% to $1.0894. Brenmiller recently reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
</ul>
Commodities In commodity news, oil traded down 1.6% to $72.41 while gold traded down 0.3% at $2,520.70.
Silver traded down 1.9% to $28.60 on Tuesday, while copper fell 3.3% to $4.0730.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.4% and France's CAC 40 fell 0.3%. Spain's IBEX 35 Index fell 0.7%, while London's FTSE 100 fell 0.5%.
French government budget deficit shrank to EUR 156.91 billion in January to July compared to EUR 168.99 billion in the year-ago period last year. The number of people registering as jobless in Spain increased by 0.9% month-over-month to 2.6 million in August. UK's retail sales increased 0.8% year-over-year in August.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.04%, Hong Kong's Hang Seng Index falling 0.23%, China's Shanghai Composite Index declining 0.29% and India's BSE Sensex falling 0.005%.
Singapore's manufacturing PMI rose to 50.9 in August from 50.7 in the prior month.
Economics
<ul>
<li>The Logistics Manager's Index fell to 56.4 in August compared to 56.5 in July.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to 47.9 in August versus a preliminary reading of 48.</li>
<li>The ISM manufacturing PMI rose to 47.2 in August from 46.8 in the prior month, missing market estimates of 47.5.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday.
Shares of Dyne Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NYSE">DYN</a>) fell sharply in today's pre-market trading after the company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement <a href="https://www.benzinga.com/quote/DYN">in multiple cohorts.</a>
Dyne Therapeutics shares dipped 15.6% to $38.89 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares fell 7.2% to $76.07 in pre-market trading.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares fell 5.8% to $35.70 in pre-market trading. Vice President Kamala Harris has expressed her support for American ownership of United States Steel, amidst ongoing foreign acquisition attempts.</li>
<li>Diversified Energy Company PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) fell 5.6% to $11.54 in pre-market trading. Keybanc analyst Tim Rezvan, last week, initiated coverage on Diversified Energy with an Overweight rating and announced a price target of $18.</li>
<li>LG Display Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPL#NYSE">LPL</a>) shares fell 4.4% to $3.96 in pre-market trading.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) shares declined 4.1% to $2.60 in pre-market trading.</li>
<li>Hafnia Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NASDAQ">HAFN</a>) fell 4.1% to $7.43 in pre-market trading.</li>
<li>BHP Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) shares fell 4% to $52.90 in pre-market trading</li>
<li>Hafnia Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NYSE">HAFN</a>) fell 3.4% to $7.48 in pre-market trading.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares declined 3.2% to $21.78 in pre-market trading. PureTech Health, last week, reported a year-over-year decrease in H1 financial results.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares slipped 2.6% to $169.15 in pre-market trading  ahead of the Sept. 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

ACHC

ALTM

HAFN

PRTC

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Dyne Therapeutics shares are trading lower. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024

Dyne Therapeutics Announced New Clinical Data From Its Ongoing Phase 1/2 DELIVER Trial Of DYNE-251 In Patients With Duchenne Muscular Dystrophy Who Are Amenable To Exon 51 Skipping, Demonstrating Dystrophin Expression And Functional Improvement In Multiple Cohorts

Avidity gets FDA partial clinical hold lifted on DM1 drug candidate

Capricor stock rallies 20% on DMD data presentation update

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 10x Genomics (TXG – Research Report), Dyne Therapeut...

Analysts' Top Healthcare Picks: 10x Genomics (TXG), Dyne Therapeutics (DYN)

Capricor reports positive long-term data for DMD drug deramiocel

JPMorgan analyst Tessa Romero downgraded Dyne Therapeutics (DYN) to Neutral from Overweight with a price target of $35, down from $43. While the sh...

Dyne Therapeutics downgraded to Neutral from Overweight at JPMorgan

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

"We've made significant progress in our ACHIEVE and DELIVER trials. We are very pleased to have received IND clearance for DYNE-101 and plan to rep...

Dyne Therapeutics reports Q3 EPS (96c), consensus (71c)

Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target at $52.00...

Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates

ALNY

CAPR

CATX

CGEM

CGON

CPRX

EWTX

HAFC

IDYA

IOVA

JANX

KURA

MRUS

MSCLF

NRIX

NUVL

PEPG

RGNX

RHHBY

SIRI

SLDB

SNDX

TRDA

VRTX

Legal

Press Releases

Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm

Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Comments

Dyne Therapeutics

ニュース

最新ニュース Dyne Therapeutics (NASDAQ:DYN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル